Glaukos (NYSE:GKOS) COO Joseph Gilliam Sells 19,340 Shares

Glaukos Corporation (NYSE:GKOS) COO Joseph Gilliam sold 19,340 shares of the stock in a transaction on Tuesday, November 18th. The stock was sold at an average price of $90.00, for a total transaction of $1,740,600.00. Following the sale, the chief operating officer owned 92,366 shares of the company’s stock, valued at approximately $8,312,940. This trade represents a 17.31% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Glaukos Stock Performance

Shares of GKOS opened at $95.26 on Friday. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.51 and a quick ratio of 4.69. Glaukos Corporation has a one year low of $73.16 and a one year high of $163.71. The stock has a 50-day moving average of $84.38 and a 200-day moving average of $91.32. The company has a market cap of $5.47 billion, a PE ratio of -61.86 and a beta of 0.81.

Glaukos (NYSE:GKOS) last posted its earnings results on Wednesday, October 29th. The medical instruments supplier reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.11. The company had revenue of $133.54 million during the quarter, compared to the consensus estimate of $122.55 million. Glaukos had a negative net margin of 18.65% and a negative return on equity of 7.53%. The firm’s revenue for the quarter was up 38.1% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.28) earnings per share. Glaukos has set its FY 2025 guidance at EPS. On average, equities research analysts predict that Glaukos Corporation will post -1.08 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. Norges Bank bought a new position in Glaukos during the 2nd quarter worth about $76,314,000. Primecap Management Co. CA boosted its position in shares of Glaukos by 50.0% in the 2nd quarter. Primecap Management Co. CA now owns 1,827,998 shares of the medical instruments supplier’s stock worth $188,814,000 after purchasing an additional 609,523 shares in the last quarter. Alliancebernstein L.P. grew its stake in Glaukos by 38.5% during the 3rd quarter. Alliancebernstein L.P. now owns 1,733,474 shares of the medical instruments supplier’s stock worth $141,365,000 after buying an additional 481,620 shares during the last quarter. AustralianSuper Pty Ltd acquired a new position in shares of Glaukos during the second quarter valued at about $41,946,000. Finally, William Blair Investment Management LLC grew its position in Glaukos by 52.4% during the 2nd quarter. William Blair Investment Management LLC now owns 1,136,095 shares of the medical instruments supplier’s stock worth $117,347,000 after purchasing an additional 390,805 shares during the last quarter. Institutional investors own 99.04% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have commented on GKOS. JPMorgan Chase & Co. raised their price target on shares of Glaukos from $110.00 to $120.00 and gave the company an “overweight” rating in a report on Thursday, October 30th. Needham & Company LLC boosted their price target on shares of Glaukos from $115.00 to $117.00 and gave the stock a “buy” rating in a research note on Thursday, October 30th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Glaukos in a research note on Wednesday, October 8th. BTIG Research upped their price objective on shares of Glaukos from $104.00 to $116.00 and gave the stock a “buy” rating in a report on Thursday, October 30th. Finally, Zacks Research cut Glaukos from a “strong-buy” rating to a “hold” rating in a research note on Friday, August 15th. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $119.08.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.